Ralph Lippe

688 total citations
26 papers, 469 citations indexed

About

Ralph Lippe is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Ralph Lippe has authored 26 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Rheumatology, 16 papers in Immunology and 14 papers in Hematology. Recurrent topics in Ralph Lippe's work include Spondyloarthritis Studies and Treatments (16 papers), Autoimmune and Inflammatory Disorders Research (14 papers) and Psoriasis: Treatment and Pathogenesis (12 papers). Ralph Lippe is often cited by papers focused on Spondyloarthritis Studies and Treatments (16 papers), Autoimmune and Inflammatory Disorders Research (14 papers) and Psoriasis: Treatment and Pathogenesis (12 papers). Ralph Lippe collaborates with scholars based in Germany, United States and Canada. Ralph Lippe's co-authors include Iain B. McInnes, Ryan DeMasi, Klaus Krüger, Janet Pope, Paul Emery, Blerina Kola, Sadiq Lula, Zoltán Szekanecz, Joseph F. Merola and Apinya Lertratanakul and has published in prestigious journals such as The Journal of Immunology, Frontiers in Immunology and Lara D. Veeken.

In The Last Decade

Ralph Lippe

24 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ralph Lippe Germany	14	279	268	153	69	37	26	469
Mykola Stanislavchuk Ukraine	8	358 1.3×	200 0.7×	197 1.3×	162 2.3×	21 0.6×	34	546
M. Lamba United States	8	100 0.4×	138 0.5×	76 0.5×	89 1.3×	92 2.5×	17	356
Eric Helmer Belgium	8	117 0.4×	301 1.1×	68 0.4×	28 0.4×	97 2.6×	18	497
Yeong-Wook Song South Korea	8	207 0.7×	89 0.3×	69 0.5×	43 0.6×	10 0.3×	13	382
Foteini Strimenopoulou United Kingdom	6	156 0.6×	308 1.1×	99 0.6×	25 0.4×	126 3.4×	10	435
Katarzyna Gębura Poland	12	89 0.3×	145 0.5×	73 0.5×	66 1.0×	14 0.4×	22	349
Caterina Baldi Italy	10	158 0.6×	100 0.4×	45 0.3×	42 0.6×	21 0.6×	52	423
Pascale Pellet Switzerland	7	301 1.1×	331 1.2×	216 1.4×	30 0.4×	51 1.4×	12	544
Shankar Revu United States	9	88 0.3×	234 0.9×	33 0.2×	82 1.2×	23 0.6×	14	404
Laurindo Ferreira da Rocha Brazil	11	119 0.4×	170 0.6×	32 0.2×	64 0.9×	24 0.6×	17	377

Countries citing papers authored by Ralph Lippe

Since Specialization

Citations

This map shows the geographic impact of Ralph Lippe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph Lippe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph Lippe more than expected).

Fields of papers citing papers by Ralph Lippe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph Lippe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph Lippe. The network helps show where Ralph Lippe may publish in the future.

Co-authorship network of co-authors of Ralph Lippe

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph Lippe. A scholar is included among the top collaborators of Ralph Lippe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph Lippe. Ralph Lippe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Coates, Laura C., Ricardo Blanco, Frank Behrens, et al.. (2025). Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies. RMD Open. 11(3). e005522–e005522.

Gossec, Laure, Andra Bălănescu, Alexis Ogdie, et al.. (2025). Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials. Arthritis Research & Therapy. 28(1). 2–2.

Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2024). Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and Therapy. 11(3). 633–648. 9 indexed citations

Kavanaugh, Arthur, Philip J. Mease, Laure Gossec, et al.. (2024). Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT‐PsA 1 and 2 Randomized Controlled Trials. ACR Open Rheumatology. 6(11). 736–745. 2 indexed citations

Burmester, Gerd R, Andrea Rubbert‐Roth, Valderílio Feijó Azevedo, et al.. (2024). Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatology and Therapy. 11(3). 737–753. 6 indexed citations

Kristensen, Lars Erik, Mauro Waldemar Keiserman, Kim Papp, et al.. (2024). Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial. Rheumatology and Therapy. 11(3). 617–632. 8 indexed citations

Gordon, Kenneth B., Andrew Blauvelt, H. Bachelez, et al.. (2024). Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials. Dermatology and Therapy. 14(9). 2523–2538. 10 indexed citations

Charles‐Schoeman, Christina, Ernest Choy, Iain B. McInnes, et al.. (2023). MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 9(4). e003392–e003392. 17 indexed citations

Rubbert‐Roth, Andrea, Adriana María Kakehasi, Tsutomu Takeuchi, et al.. (2023). Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatology and Therapy. 11(1). 97–112. 16 indexed citations

10.

Taylor, Peter C., Ernest Choy, Xenofon Baraliakos, et al.. (2023). Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Lara D. Veeken. 63(2). 298–308. 45 indexed citations

11.

McInnes, Iain B., Koji Kato, Marina Magrey, et al.. (2022). Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. Rheumatology and Therapy. 10(1). 275–292. 28 indexed citations

12.

Mease, Philip J., Arthur Kavanaugh, Dafna D. Gladman, et al.. (2022). Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. Rheumatology and Therapy. 9(4). 1181–1191. 3 indexed citations

13.

Strand, Vibeke, Filip Van den Bosch, Roberto Ranza, et al.. (2021). Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. Rheumatology and Therapy. 8(4). 1827–1844. 14 indexed citations

14.

Burmester, Gerd R, Kevin Winthrop, Ricardo Blanco, et al.. (2021). Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatology and Therapy. 9(2). 521–539. 35 indexed citations

15.

Aletaha, Daniel, M. Elaine Husni, Joseph F. Merola, et al.. (2020). <p>Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study</p>. Patient Preference and Adherence. Volume 14. 949–961. 13 indexed citations

16.

Behrens, Frank, Jörg C. Prinz, Jürgen Jobst, et al.. (2018). Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs. The Journal of Rheumatology. 45(6). 802–810. 1 indexed citations

17.

Emery, Paul, Janet Pope, Klaus Krüger, et al.. (2018). Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. Advances in Therapy. 35(10). 1535–1563. 62 indexed citations

18.

Gaubitz, M., et al.. (2017). Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study. Clinical Rheumatology. 36(9). 1989–1996. 8 indexed citations

19.

Ohl, Kim, Ralph Lippe, Angela Schippers, et al.. (2016). CREM Alpha Enhances IL-21 Production in T Cells In Vivo and In Vitro. Frontiers in Immunology. 7. 618–618. 10 indexed citations

20.

Varga, Georg, Jan Ehrchen, Toni Weinhage, et al.. (2014). Immune Suppression via Glucocorticoid-Stimulated Monocytes: A Novel Mechanism To Cope with Inflammation. The Journal of Immunology. 193(3). 1090–1099. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact